Integrating data from preclinical orthografts and clinical PCa cohorts, we modelled regulon signatures to identify patients at risk of cancer recurrence, and identified the JMJD6 (Jumonji Domain Containing 6, arginine demethylase and lysine hydroxylase, a protein hydroxylase or histone demethylase) regulon as a prognostic marker in PCa (Figure 1). This evidence concerns the gene JMJD6 and posterior cortical atrophy.